Raphael Pharmaceutical Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Raphael Pharmaceutical Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($255.0K) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($322.0K) | Aug 13, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($322.0K) | Nov 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($429.0K) | May 15, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($429.0K) | Nov 13, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($429.0K) | Aug 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($326.0K) | Nov 13, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($248.0K) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($248.0K) | Aug 13, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($550.0K) | Nov 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($550.0K) | May 15, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($550.0K) | Aug 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($725.0K) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($417.0K) | Aug 12, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($681.0K) | Nov 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($264.0K) | May 15, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($264.0K) | Aug 12, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($1.44M) | Nov 14, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($812.0K) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($627.0K) | Aug 9, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($251.0K) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($315.0K) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($425.0K) | May 15, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($319.0K) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($249.0K) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($547.0K) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($729.0K) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($419.0K) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($258.0K) | May 15, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($1.43M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($612.0K) | Aug 9, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($175.0K) | May 15, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($418.0K) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($385.0K) | Aug 12, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($252.0K) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($235.0K) | Nov 16, 2021 |